Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/217223
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2

AutorRiggioni, Carmen; Comberiat, Pasquale; Giovannini, Mattia; Agache, Ioana; Akdis, Mubeccel; Alves-Correia, Magna; Antó, Josep M.; Arcolaci, Alessandra; Azkur, Ahmet Kursat; Azkur, Dilek; Beken, Burcin; Boccabella, Cristina; Bousquet, Jean; Breiteneder, Heimo; Carvalho, Daniela; Vecillas, Leticia de las; Diamant, Zuzana; Eguiluz-Gracia, Ibon; Eiwegger, Thomas; Eyerich, Stephanie; Fokkens, Wytske; Gao, Ya-dong; Hannachi, Farah; Johnston, Sebastian L.; Jutel, Marek; Karavelia, Aspasia; Klimek, Ludfger; Moya, Beatriz; Nadeau, Kari C.; O'Hehir, Robin; O'Mahony, Liam; Pfaar, Oliver; Sanak, Marek; Schwarze, Jürgen; Sokolowska, Milena; Torres Jaén, María José; Veen, Willem van de; Zelm, Menno C. van; Wang, De Yun; Zhang, Luo; Jiménez Saiz, Rodrigo CSIC ORCID; Akdis, Cezmi A.
Palabras claveAllergy
Coronavirus disease 2019
COVID-19
SARS‐CoV‐2
Severe acute respiratory syndrome–related coronavirus 2
Fecha de publicación14-jun-2020
EditorJohn Wiley & Sons
CitaciónAllergy (2020)
ResumenIn December 2019, China reported the first cases of the coronavirus disease 2019 (COVID‐19). This disease, caused by the severe acute respiratory syndrome–related coronavirus 2 (SARS‐CoV‐2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID‐19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence‐based medical advice on SARS‐CoV‐2 and COVID‐19. Although the majority of the patients show a very mild, self‐limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID‐19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID‐19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID‐19–related topics should be based on more coordinated high‐quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS‐CoV‐2, COVID‐19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID‐19 and allergic disease.
Versión del editorhttps://doi.org/10.1111/all.14449
URIhttp://hdl.handle.net/10261/217223
DOI10.1111/all.14449
ISSN0105-4538
E-ISSN1398-9995
Aparece en las colecciones: (PTI Salud Global) Colección Especial COVID-19
(CNB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

66
checked on 12-mar-2024

SCOPUSTM   
Citations

85
checked on 27-mar-2024

WEB OF SCIENCETM
Citations

77
checked on 26-feb-2024

Page view(s)

234
checked on 28-mar-2024

Download(s)

49
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.